-
Watch HOPE Summit 2026 Videos
HOPE Summit 2026 was filled with old friends reuniting, new friends being made, and of course, plenty of inspirational and informative sessions designed to help people live well with lung cancer.
For...
IN THE SPOTLIGHT
-
Clinical Trial Access Isn’t Expanding. It’s Concentrating.
Clinical trials show us whether a new treatment is safe and effective. They are also an important way for patients to access cutting-edge care. For trials to truly serve the lung... -
Podcast: Lung Cancer Diagnosis—What Happens Next
What happens after a lung cancer diagnosis? In this first episode of LUNGevity’s Lung Cancer Voices of Hope podcast, lung cancer survivor Lisa Bistline shares her experience, from... -
Podcast: Why Community Matters in Lung Cancer Care
Why does finding community matter in lung cancer care? In this episode, lung cancer survivor and advocate Jill Feldman shares her experience, from losing multiple family members to... -
Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss
This video is a recording from a LUNGevity virtual meetup. Each month, we host multiple virtual meetups for those impacted by lung cancer to meet and connect with others who... -
Weekly Virtual Meetup
For patients/survivors - Join us every Tuesday at 12 pm ET for this general meetup for anyone impacted by lung cancer. After registering, you will receive a confirmation email... -
Meet The “Mini-Organs” of Lung Cancer Research
Though many of us would like to deny it, our neighbors affect us. Their loud music disturbs our sleep. The scent of their dinner wafts through an open window. The sight of their... -
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung... -
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both...
Efficacy and safety of sintilimab combined with histology-specific chemotherapy in advanced NSCLC: a real-world retrospective study
Efficacy and safety of sintilimab combined with histology-specific chemotherapy in advanced NSCLC: a real-world retrospective study
Prognostic impact of invasive features in completely resected NSCLC stratified by tumor diameter
Prognostic impact of invasive features in completely resected NSCLC stratified by tumor diameter
Adjuvant Selpercatinib Deemed ‘Immediately Practice-Changing’ in Early-Stage RET Fusion–Positive NSCLC
Adjuvant Selpercatinib Deemed ‘Immediately Practice-Changing’ in Early-Stage RET Fusion–Positive NSCLC
High PD-L1 Expression Linked To Shorter PFS With First-Line ALK TKIs In ALK-Rearranged NSCLC
High PD-L1 Expression Linked To Shorter PFS With First-Line ALK TKIs In ALK-Rearranged NSCLC
阿美替尼「靶化」方案 4 周期实现颅内和颅外 PR --一例合并 TP53 等抑癌基因共突变并伴脑转移的 EGFR 突变晚期 NSCLC 病例的启示_腾讯新闻
ASCO 2026: Targeted and Immunotherapy Advances in Advanced NSCLC
GPNMB-ECD drives acquired resistance to osimertinib in NSCLC via inducing tumor cell cytoskeletal reorganization
GPNMB-ECD drives acquired resistance to osimertinib in NSCLC via inducing tumor cell cytoskeletal reorganization
Peripheral blood IFN-γ–producing T-cell subsets and soluble IL-2 receptor as independent prognostic biomarkers in NSCLC treated with immune checkpoint inhibitor–based therapy
Peripheral blood IFN-γ–producing T-cell subsets and soluble IL-2 receptor as independent prognostic biomarkers in NSCLC treated with immune checkpoint inhibitor–based therapy